However, there are also discrepant results that observed higher total circulating IGF-1 levels and higher molar ratios of IGF-1/IGFBP3 (an indicator of bioavailable IGF-1) in the AD group compared to the age-matched healthy group [31], [32]. This evidence concerns the gene IGF1 and Alzheimer disease.